Back
Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
Journal article

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

  • Medaglini D Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Siegrist CA World Health Organization Collaborating Center for Vaccine Immunology, Departments of Pathology-Immunology, University of Geneva, 1211 Geneva, Switzerland. Electronic address: claire-anne.siegrist@unige.ch.
  • 2017-05-02
Published in:
  • Current opinion in virology. - 2017
Drug Carriers
Ebola Vaccines
Ebolavirus
Gene Expression Profiling
Hemorrhagic Fever, Ebola
Humans
Immunoassay
Metabolome
Vaccines, Synthetic
Vesiculovirus
English The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/46696
Statistics
Document views: 32 File downloads: